Share on StockTwits

SAGE Therapeutics (NASDAQ:SAGE) announced its earnings results on Thursday. The company reported ($4.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by $3.34, Stock Ratings Network reports.

Shares of SAGE Therapeutics (NASDAQ:SAGE) opened at 29.58 on Thursday. SAGE Therapeutics has a 52 week low of $24.25 and a 52 week high of $34.88. The stock has a 50-day moving average of $28.95 and a 200-day moving average of $28.95. The company’s market cap is $738.3 million.

A number of analysts have recently weighed in on SAGE shares. Analysts at Canaccord Genuity initiated coverage on shares of SAGE Therapeutics in a research note on Tuesday. They set a “buy” rating and a $40.00 price target on the stock. On a related note, analysts at JPMorgan Chase & Co. initiated coverage on shares of SAGE Therapeutics in a research note on Tuesday. They set an “overweight” rating and a $42.00 price target on the stock. Finally, analysts at Goldman Sachs initiated coverage on shares of SAGE Therapeutics in a research note on Tuesday. They set a “neutral” rating and a $38.00 price target on the stock.

SAGE Therapeutics, Inc is a biopharmaceutical company. The Company is focused on development and commercialization of therapies for the treatment of life-threatening, rare central nervous system (NASDAQ:SAGE) disorders.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.